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Our  current  understanding  of  cystic  ﬁbrosis  (CF)  has  revealed  that  the  biophysical  properties  of  mucus
play a  considerable  role  in  the pathogenesis  of  the  disease  in view  of  the  fact that  most  mucus-producing
organs  are affected  in CF  patients.  In this  review,  we  discuss  the  potential  causal  relationship  between
altered  cystic  ﬁbrosis  transmembrane  conductance  regulator  (CFTR)  function  and  the  production  of
mucus  with  abnormal  biophysical  properties  in the  intestine  and  lungs,  highlighting  what  has  been
learned  from  cell cultures  and  animal  models  that  mimic  CF  pathogenesis.  A similar  cascade  of events,
including  mucus  obstruction,  infection  and  inﬂammation,  is  common  to all  epithelia  affected  by impaired
surface  hydration.  Hence,  the  main  structural  components  of  mucus,  namely  the  polymeric,  gel-forming
mucins,  are  critical  to the  onset  of the  disease.  Defective  CFTR  leads  to epithelial  surface  dehydration,
altered  pH/electrolyte  composition  and  mucin  concentration.  Further,  it  can  inﬂuence  mucin transition
from  the  intracellular  to extracellular  environment,  potentially  resulting  in  aberrant  mucus  gel  formation.
While  defective  HCO3− production  has  long  been  identiﬁed  as a feature  of  CF,  it has  only  recently  been
considered  as  a key  player  in  the  transition  phase  of mucins.  We  conclude  by examining  the inﬂuence
of  mucins  on  the biophysical  properties  of  CF  sputum  and  discuss  existing  and  novel therapies  aimed  at
removing  mucus  from  the  lungs.
This  article is part  of  a  Directed  Issue  entitled:  Cystic  Fibrosis:  From  o-mics  to cell  biology,  physiology,
and  therapeutic  advances.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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. Introduction
CF is the most common genetic disease, occurring prevalently in
he Caucasian population at a rate of 1 in 2500 newborns of North-
rn European descent. The most common symptoms of CF include
rogressive lung disease and chronic digestive conditions, which
re the result of mutations of the cystic ﬁbrosis transmembrane
onductance regulator (CFTR) (Riordan et al., 1989). Depending on
enetic and environmental factors, symptom severity varies among
ndividuals carrying CFTR mutations. More speciﬁcally, CF patho-
enesis is characterised by the build-up of thick, sticky mucus in
ultiple mucin-producing organs, such as the lungs, sinuses, intes-
ine, pancreas and reproductive organs. For this reason, CF is also
nown as mucoviscidosis, suggesting that polymeric, gel-forming
ucins, the large O-linked glycoproteins responsible for the vis-
oelastic properties of mucus, play a critical role in the disease
Kreda et al., 2012).
Since the discovery of the defective CF gene in 1989, almost
000 mutations have been reported and are available in the Cys-
ic Fibrosis Mutation Database.1 The CFTR gene encodes for a
yclic adenosine monophosphate (cAMP) regulated chloride chan-
el expressed in apical membranes of various epithelia (Gregory
t al., 1990). In addition to controlling chloride secretion, this
hannel regulates the function of other membrane proteins, includ-
ng the epithelial sodium channel (ENaC) (Briel et al., 1998). Both
FTR and ENaC play an important role in maintaining homeosta-
is by controlling the movement of water through the epithelium,
hich is particularly important for mucous membranes. Hence,
FTR malfunction leads to ﬂuid hyperabsorption and subsequent
ehydration of the epithelial surface, which, in turn, results in
bnormal mucus gel with an increased polymeric mucin concen-
ration and altered biophysical properties (Boucher, 2007; Button
t al., 2012).
Among other tissues, CFTR is expressed in the pancreas,
ntestine, lungs, and reproductive tract, and each organ-speciﬁc
henotype can be related to the production of aberrant mucus
ith altered biophysical properties (Burgel et al., 2007; Malmberg
t al., 2006; Reid et al., 1997). Common symptoms exhibited in
ucin-producing organs are blocked ducts and impaired mucosal
efence. In this review, we focus on the role of CFTR in the intes-
ine and lungs since these organs have been the subject of most
tudies involving the biophysical properties of mucins. By control-
ing ﬂuid secretion and regulating ion composition in these organs,
FTR plays a critical role in mucosal defence by modulating the
iophysical properties of mucus and assisting in bacterial killing
Norkina et al., 2004a; Pezzulo et al., 2012; Puchelle et al., 2002).
bnormal modulation of epithelial inﬂammation related to CFTR
alfunction may  further contribute to CF pathophysiology, but the
ink has yet to be established. CFTR also plays an important role
n the transcellular secretion of bicarbonate (HCO3−), an alkalis-
ng agent that plays a crucial physiological role in pH buffering.
lthough impaired bicarbonate secretion was reported early in
he discovery of the disease (Hadorn et al., 1968), the role of this
nion in CF has only recently been a major focus of interest within
he mucus/mucin community. As highlighted by Quinton (2008),
F individuals suffer from complications in all mucin-secreting
rgans, which may  be a consequence of defective HCO3− trans-
ort. Consistent with this idea, reduced HCO3− secretion in CF may
e responsible for lowered epithelial surface pH, which has been
hown to impede bacterial killing (Pezzulo et al., 2012) and increase
ucus/mucin viscoelasticity (Celli et al., 2005; Georgiades et al.,
013). More speciﬁcally, there is emerging evidence that HCO3−
lays a key role in the expansion of polymeric mucins after their
1 http://www.genet.sickkids.on.ca/cftr/ConsortiumDataPage1.html.mistry & Cell Biology 52 (2014) 136–145 137
secretion into the extracellular milieu that is essential for normal
mucus gel formation and transport (Chen et al., 2010; Cooper et al.,
2013).
Before the use of physiotherapy (to remove mucus from the
lungs) and enzyme therapy (e.g., pancreatic enzymes to correct
digestive enzyme insufﬁciency and inhaled DNase treatment to
alter mucus properties), CF was considered to be a fatal childhood
disease. However, with improved therapies and strategies for man-
aging the disease, the average life expectancy for CF patients is
now 37 years.2 In recent years, small molecule therapies directed
at restoring CFTR functionality have yielded success with a small
number of mutations and are being pursued for other, more
common mutations. Indeed, the goal of developing CFTR-speciﬁc
therapies for all patients is currently a key objective of the Cys-
tic Fibrosis Foundation. In the meantime, alternative approaches
are being investigated (e.g., the use of mucolytics, inhibitors of
mucin secretion and osmotic agents) to address the problem of
mucus accumulation/obstruction in CF patients. In this article, we
will review the current understanding of mucus and mucins in
CF, describe how inefﬁcient post-secretory mucin expansion may
result in mucus with aberrant physical properties, and conclude by
discussing therapies aimed at removing mucus from the lungs.
2. Consequences of CFTR mutations for mucus
The molecular mechanisms by which CFTR mutations can dis-
rupt CFTR function include defects in protein synthesis (class I),
maturation/trafﬁcking (class II, e.g., F508, the most common
mutation with nearly 90% of patients carrying at least one allele),
channel gating (class III, e.g. G551D, the target of Kalydeco; see
Section 4), altered conductance (class IV) and decreased CFTR abun-
dance (class V) (Ferec and Cutting, 2012). As mentioned above,
these defects lead to deﬁcient cAMP-dependent Cl− and HCO3−
secretion and enhanced ENaC-mediated Na+ absorption in affected
epithelia, resulting in dehydration of the mucus and concentration
of its components (e.g., mucins) (Boucher, 2007). As a result, the
majority of CF patients require a daily routine of inhaled thera-
pies and exercise to prevent the progression of lung disease or a
decrease in lung function. Additionally, most CF patients suffer from
gastrointestinal (GI) manifestations regardless of their genotype. A
similar pathogenesis cascade of obstruction, infection and inﬂam-
mation is observed in the airways and intestines and is thought to
be the direct result of epithelial surface dehydration and abnormal
electrolyte composition.
2.1. Changes in mucus properties in the intestine
Expression of the CFTR gene in the GI tract is low in the stomach
and rises in the intestine, displaying a gradient with the highest
mRNA levels in the duodenum and lowest levels in the large intes-
tine (Strong et al., 1994). This pattern of expression may  reﬂect
the need for acid neutralisation via HCO3− secretion as the prox-
imal intestine receives a highly acidic bolus from the stomach. In
addition to exhibiting high levels of CFTR expression, the normal
intestine receives large volumes of HCO3−-rich material from the
pancreas. Proper pH buffering and ﬂuid secretion in the intestine is
essential for the optimal functioning of digestive enzymes and the
maintenance of normal bacterial ﬂora. In the case of CF, the combi-intestinal mucus facilitates bacterial growth in the GI  tract (De
Lisle and Borowitz, 2013; Fridge et al., 2007; Lisowska et al., 2009).
Mucus adhesion to the intestinal wall may  be related to mucin
2 http://www.CFF.org.
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yperconcentration and/or abnormal mucin expansion upon gran-
le exocytosis (Garcia et al., 2009; Kesimer et al., 2010; Verdugo,
012b); this latter process will be discussed in more depth, below
see Section 3.1). The most serious acute complication of the CF
ntestinal phenotype is the obstruction of the terminal ileum or
roximal large intestine, referred to as meconium ileus, which
ccurs frequently in CF neonates with severe genotypes (Feingold
nd Guilloud-Bataille, 1999). Meconium ileus, which is a complex,
ucin-rich substance (Schachter and Dixon, 1965), can be surgi-
ally removed or washed out with osmotic agents but if untreated
an result in the rupture of the intestinal wall and sepsis (De Lisle
nd Borowitz, 2013). Other consequences of CFTR mutations in the
ntestine include an abnormal GI microbiota with altered diversity,
ocation and density, and increased inﬂammation, which leads to
lcerations in 60% of CF patients as revealed by a new endoscopy
echnique relying on swallowed capsules (PillCam) (Werlin et al.,
010).
Gene-targeted animal models (e.g., mice, pigs and ferrets) lack-
ng CFTR or Cftr expression develop meconium ileus at birth,
onﬁrming the importance of CFTR in the GI tract (Rogers et al.,
008; Snouwaert et al., 1992; Sun et al., 2010). Cftr mutant
ouse models, which include both Cftr point mutations (e.g.,
ftrF508/F508) and complete Cftr knockouts (e.g., Cftr−/−), have
reatly contributed to our understanding of the GI manifestations
f CF. However, Cftr mutant mice develop only mild lung pheno-
ypes, likely due to compensation mechanisms that stimulate other
l− channels, such that these mice are not as effective for study-
ng CF lung pathogenesis. The major intestinal phenotypes in CF
ouse models are obstruction, bacterial colonisation and inﬂam-
ation (Guilbault et al., 2007; Lynch et al., 2013). Mucus adhesion
ontributes to bacterial colonisation in CF mice, which can be alle-
iated by laxative treatment (De Lisle et al., 2007). Although a direct
ausal relationship between bacterial colonisation and inﬂamma-
ion has not yet been established, CF mice exhibit increased levels of
eutrophils, mast-cells and inﬂammatory markers (Norkina et al.,
004b). The slow intestinal transit due to abnormal mucus biophys-
cal properties appears to initiate a cascade of events that promote
hronic bacterial infection and inﬂammation.
.2. Impact on mucociliary clearance in the lungs
Although CFTR mutations affect several organs, the progression
f lung disease can be particularly life-threatening. Despite much
mprovement in therapies, pulmonary complications are still the
ajor cause of morbidity and mortality in CF patients. CF indi-
iduals experiencing a rapid decline in lung function typically
isplay poor survival rate unless they undergo lung transplanta-
ion (Rosenbluth et al., 2004). The production of “abnormal” mucus
ith aberrant rheological properties in the lungs leads to a cascade
f events that involve mucus adhesion to epithelial surfaces, air-
ay plugging, chronic bacterial infection and inﬂammation (Button
t al., 2012; Mall et al., 2004; Stoltz et al., 2010). Once these early
vents (i.e., mucus stasis and/or bacterial infection) take place in the
ungs, complex feedback mechanisms ensue. For instance, bacterial
nfection stimulates goblet cell hyperplasia and the recruitment
f neutrophils (Cash et al., 1979), which worsen mucus viscosity
nd reduce clearance via the release of extracellular DNA (Lethem
t al., 1990; Shak et al., 1990). Impaired clearance facilitates bacte-
ial growth and bioﬁlm formation, triggering more inﬂammation
Davies, 2002; Stoltz et al., 2010). Recently, much effort from
he scientiﬁc community has focused on the speciﬁc mechanisms
nderlying the onset of lung disease in CF patients; i.e., whether
ucin concentration or impaired bacterial killing alone can prompt
F lung pathogenesis.
In CF, airway dehydration leads to airway surface liquid (ASL)
olume depletion, increased mucus concentration and reducedmistry & Cell Biology 52 (2014) 136–145
mucociliary clearance (MCC) (Boucher, 2007; Matsui et al., 1998).
Speciﬁcally, increased mucin concentration causes the osmotic
pressure of the mucus layer to increase, which draws water osmot-
ically from the periciliary layer (PCL) that is occupied, in part, by
cell-surface tethered mucins (Button et al., 2012; Kesimer et al.,
2013). Beyond a critical concentration of 5% solids, the osmotic
pressure of the mucus layer exceeds the osmotic pressure of the
PCL, initiating the collapse of the PCL. As a result of this collapse,
cilia are compressed and unable to beat. The mucus layer adheres to
the cell surfaces of the epithelium, causing MCC  to cease. Mucus sta-
sis eventually leads to airway plugging, chronic bacterial infection,
inﬂammation and airway tissue damage (bronchiectasis).
As mentioned earlier, Cftr mutant mice develop only mild lung
phenotypes. However, it was still possible to validate the hypothe-
sis that airway dehydration promotes mucus plugging and triggers
inﬂammation using a mouse model that overexpresses the  sub-
unit of the Na+ channel in the lungs, also called the ENaC mouse
(Mall et al., 2004). This model has demonstrated that acceler-
ated Na+ transport alone produces a CF-like lung phenotype that
exhibits PCL collapse, slowed MCC  rate, mucus obstruction and neu-
trophilic inﬂammation (Fig. 1). ENaC-overexpressing neonates
show a temporary increase in bacterial burden that appears to
resolve by adulthood (Livraghi-Butrico et al., 2012). Interestingly,
ENaC-overexpressing animals born and housed in germ-free
(gnotobiotic) and LPS-free conditions developed and maintained
an inﬂammatory phenotype, suggesting that mucus dehydration
alone is sufﬁcient to trigger airway inﬂammation (Livraghi-Butrico
et al., 2012). These results imply that the epithelium responds to
an abnormal mucus layer by initiating the recruitment of neu-
trophils. These early events instigate a vicious cycle in the lungs
as dying neutrophils entrapped in thick mucus release their DNA
and worsen the rheological properties of mucus (Lethem et al.,
1990; Shak et al., 1990). This thick, immobile mucus provides an
optimal environment for bacterial growth and, consequently, sti-
mulates further mucin release and neutrophil inﬁltration (Knowles
and Boucher, 2002; Smith, 1997; Wanner et al., 1996).
In contrast with the mouse, the CF pig model that expresses
a mutant form (e.g., −/F508) spontaneously develops the fea-
tures of CF lung disease, including infection (Stoltz et al., 2010).
In this model, airways can be completely occluded with tenacious,
adherent mucus, resembling mucus observed in human CF lungs.
Histopathology has revealed that these mucus plaques exhibit a
lamellar appearance, suggesting that the progressive deposition of
mucus is the result of slowed MCC. Within hours of birth (6–12 h),
CF pigs show no inﬂammation but increased bacterial burden. The
impaired ability to eradicate bacteria is related to lowered ASL pH,
which can be directly linked to the inability of CF airways to secrete
HCO3− (Pezzulo et al., 2012; Stoltz et al., 2010). Although HCO3−
plays a critical role in bacterial killing, the mucus obstructive phe-
notype is not exclusively related to defective HCO3− secretion since
the ENaC mouse model develops mucus plugging subsequent to
airway dehydration.
3. Polymeric, gel-forming mucins
The molecular framework and biophysical properties of mucus
are provided in large part by the high-molecular-weight (Mr  2-
100 MDa) polymeric gel-forming mucins (Sheehan et al., 1986).
The products of 5 genes (MUC genes), MUC2,  MUC5AC, MUC5B,
MUC6 and MUC19 in the human and Muc2, Muc5ac, Muc5b,  Muc6
and Muc19 in the mouse (Chen et al., 2004; Escande et al., 2004;
Thornton et al., 2008), make up this family of closely related
O-linked glycoproteins (Fig. 2). Of particular relevance to this
review are MUC2/Muc2 (Gum et al., 1994), the major intesti-
nal mucin, and MUC5AC/Muc5ac and MUC5B/Muc5b, the major
C. Ehre et al. / The International Journal of Biochemistry & Cell Biology 52 (2014) 136–145 139
Fig. 1. Formation of mucus plaques and neutrophilic inﬂammation in the ENaC mouse model. (A) AB-PAS stain of ENaC lungs revealing mucus plugs at airway branching. (B)
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dmmunohistochemistry (IHC) displaying PCL collapse and mucin accumulation on a
ronchoalveolar lavage showing a mixture of macrophages and neutrophils. (D) IHC
olor  in this legend, the reader is referred to the web version of the article.)
espiratory mucins (Thornton et al., 2008). The physicochemical
nd biological properties of these mucins are dictated by their
eavily glycosylated mucin domains. The dense glycosylation of
hese molecules (up to 80% in mass) with neutral and nega-
ively charged O-glycans stiffens the mucin polypeptide, resulting
n a high volume occupancy in solution which is important for
el-formation (Gerken, 1993). Furthermore, the extensive glycosyl-
tion protects the underlying mucin polypeptide from degradation
y host and pathogen-proteases produced during inﬂammation
nd infection (Hasnain et al., 2012; Henke et al., 2011; Innes et al.,
009) and provides speciﬁc ligands for bacterial adhesins that inﬂu-
nce the interaction of the host with commensal and pathogenic
rganisms (McGuckin et al., 2011).
Flanking the central glycosylated region are the N- and C-
erminal cysteine-rich domains of the mucin monomers, which
re important for intracellular disulphide-linked polymerisation
Asker et al., 1995, 1998a,b; Axelsson et al., 1998; Perez-Vilar and
ill, 1999); their role in this process will be discussed in more
etail below. Other cysteine-rich domains (cys-domains) interrupt
he central glycosylated regions of the mucin monomers and their
umber is different between mucins; MUC2, MUC5B and MUC5AC
ontain 2, 7 and 9 respectively (Rose and Voynow, 2006). The dif-
erent patterns of interruption of the glycosylated domains coupled
ith the tissue-speciﬁc expression of the mucins (intestinal tractor MUC2 and respiratory tract for MUC5AC and MUC5B) implies
ifferent functions for MUC2 compared with MUC5AC and MUC5B.
t has been suggested that cys-domains have a role in non-covalent,
ynamic cross-linking of mucin polymers within mucus (Ambort surfaces (green = Muc5b, blue = DAPI). (C) Inﬂammatory cells from a ENaC mouse
iting inﬂammatory cells trapped in mucus. (For interpretation of the references to
et al., 2011). One could hypothesise that their location between
the stiffened, glycosylated regions of the mucin polypeptide would
provide points of ﬂexibility within the mucin polymers that might
be important for the dynamic behaviour of the mucin polymers
in mucus, and/or during their intracellular assembly. Moreover,
cys-domains may  provide sites for proteolytic cleavage for nor-
mal  mucin turnover or degradation during infection/inﬂammation.
Further research is needed to fully elucidate the function of these
domains.
At the mucosal surfaces, mucins are produced mainly from spe-
cialised secretory cells: surface epithelial goblet cells (in the intes-
tine and lungs) and glandular mucous cells (in the lungs). In these
cells, the pre-assembled mucin polymers are stored, condensed
and dehydrated within secretory granules (Verdugo, 1991). The
release of mucin granules is regulated either by a baseline mecha-
nism or a purinergic-induced secretory pathway (Davis and Dickey,
2008). Once secreted into the extracellular environment, mucins
hydrate and expand to form a mucus gel with viscoelastic prop-
erties that depend on the entanglement of large mucin polymer
chains (Georgiades et al., 2013; Raynal et al., 2002; Verdugo et al.,
1987; Verdugo, 2012b). Other factors will inﬂuence the viscoelastic
properties of mucus, including hydration status (i.e., mucin con-
centration), ionic environment, pH, and the degree of cross-linking
(covalent and non-covalent bonds) between mucin polymeric
chains and between mucins and other components of mucus (i.e.,
globular proteins) (Ambort et al., 2011, 2012; Georgiades et al.,
2013; Raynal et al., 2003). Thus, CFTR malfunction and the resul-
tant consequences for the epithelial surface (e.g., altered mucin
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Fig. 2. Cartoon of mucin structure and assembly. (A) Polymeric, gel-forming mucins all share a common structural architecture. The N- and C-terminal domains have a high
cysteine content and these form intra- and intermolecular disulphide bonds. The central highly-glycosylated domains (mucin domains) are enriched in serine, threonine and
proline  residues and the O-glycans are covalently attached, via the linkage sugar N-acetylgalactosamine, to serine and threonine residues. The O-glycan chains are comprised
of  N-acetylglucosamine, galactose, N-acetylgalactosamine, fucose and sialic acid; galactose can be modiﬁed by sulphation. The number, length and amino acid sequence
of  these glycosylated domains differ between mucins. The glycosylated domains are interrupted with cys-domains, and the number of these cysteine-rich regions differs
between mucins. For more detailed reviews on the primary structure of MUC2, MUC5AC and MUC5B the reader is referred to the following articles – Dekker et al. (2002)
and Rose and Voynow (2006). (B) The early steps in polymeric mucin assembly are well accepted. In the endoplasmic reticulum (ER), the non-O-glycosylated polypeptide
forms dimers via disulphide bonds formed between the CK-domains. In the Golgi/trans-Golgi network (TGN), mucin dimers are O-glycosylated and then multimerise by
disulphide bonds formed between N-terminal D3 domains. There are two  mechanisms proposed for this step, multimers form from dimers of dimers (MUC5B, Ridley et al.,
2 mers 
s a2+ co
N  muc
a
e
c
i
t
3
e
F011;  Round et al., 2004; Sheehan et al., 2004; Thornton et al., 1990) or trimers of di
tate  within secretory granules. The acidic pH inside the granules and their high C
-termini (Ambort et al., 2012). After secretion mucins hydrate and expand to form
nd electrolyte concentrations and abnormal pH) will have major
ffects on the propensity of mucus gel-formation. In particular, a
urrent focus of mucin-related research in CF is the mechanism of
ntracellular mucin polymer formation and the role of HCO3− in
heir transition from an intracellular to extracellular form.
.1. Intracellular mucin polymer formation and post-secretion
xpansion
The intracellular assembly of polymeric mucins, as detailed in
ig. 2, is a complex process. Disulphide-linkage between C-terminal(MUC2, Ambort et al., 2012). The mucin multimers are then packaged in an ordered
ntent facilitates mucin organisation via non-covalent interactions between mucin
us.
domains yields dimers, which are subsequently polymerised via N-
terminal disulphide bonding (Asker et al., 1995, 1998a,b; Axelsson
et al., 1998; Perez-Vilar and Hill, 1999). The molecular details of
intracellular mucin polymer formation have best been described
for the intestinal mucin, MUC2, and have yet to be fully elucidated
for the respiratory mucins, MUC5AC and MUC5B. In brief, MUC2
dimers are reported to polymerise via N-terminal trimerisation to
yield branched polymers (Ambort et al., 2012; Godl et al., 2002),
whereas MUC5B and MUC5AC dimers polymerise via N-terminal
dimerisation to form linear polymers (Ridley et al., 2011; Round
et al., 2004; Sheehan et al., 2004; Thornton et al., 1990). Whatever
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he mechanism of polymer assembly, it has become increasingly
lear that mucin polymers are highly organised within the secretory
ranules (Ambort et al., 2012; Kesimer et al., 2010), and that this is
ecessary in order to control their rapid expansion after secretion
nto the extracellular environment to form mucus (see Verdugo,
012a for an in-depth discussion of the biophysics and dynamics
f post-secretory mucin expansion).
It has been proposed that Ca2+ ions have critical roles in the
ntragranular organisation of mucins. It has long been accepted
hat shielding the negative charge associated with the O-glycans
sialic acid and sulphate groups) by Ca2+ ions facilitates mucin
ompaction (Kuver and Lee, 2004; Verdugo et al., 1987). More
ecently, it has been suggested that Ca2+ ions, in the acidic pH
nvironment of the granule, organise the N-termini of MUC2 into
-membered ring-like structures that facilitate efﬁcient packing
Ambort et al., 2012). These authors proposed a novel model for the
ighly organised packing of MUC2 within the granule, and how this
acilitates the unpacking necessary to form the lamellar structure
eported for MUC2-rich mucin gels (Round et al., 2012). How-
ver, this model remains controversial and is incompatible with
he swelling kinetics and behaviour of mucins as they expand after
ecretion (Verdugo, 2012a,b). Moreover, whether this model can be
eneralised to MUC5AC and MUC5B, which form linear rather than
ranched polymers, has yet to be determined. Electron microscopy
mages of salivary mucins suggest that intragranular MUC5B is not
ackaged as a random coil but exists as a cross-linked structure
hat is organised around ‘nodes’ containing the terminal protein
omains of the mucin polypeptide (Kesimer et al., 2010). How-
ver, the involvement of Ca2+ ions in these ‘nodes’ has not been
etermined.
Upon mucin exocytosis onto the hydrated epithelial surface,
a2+ ions are exchanged for Na+ ions and pH is increased, leading to
 rapid expansion of the mucin polymers (Verdugo, 1991, 2012b).
lthough we currently have an incomplete understanding of the
echanism controlling this critical transition, it has been shown
hat HCO3− ions in the luminal milieu play an important role in
ucin expansion by sequestering Ca2+ ions and promoting alka-
inisation, thereby facilitating efﬁcient expansion and hydration of
he glycosylated mucin domains (Chen et al., 2010; Gustafsson et al.,
012; Quinton, 2010). This suggests that a critical function of CFTR
s regulating of the viscoelastic properties of mucus, and that HCO3−
s in short supply during the course of mucin granule exocytosis in
atients with CF. Defective HCO3−-mediated post-secretory mucin
xpansion coupled with defective hydration likely causes intestinal
lockage (Garcia et al., 2009) and airway obstruction (Cooper et al.,
013). One of the striking phenotypes exhibited by CF mice, besides
ecomium ileus, is the production of abnormal ileal mucus that is
dherent to the epithelium. This mucus is two or three times denser
han mucus of wild-type (WT) mice and less penetrable to beads the
ize of bacteria (Gustafsson et al., 2012). Remarkably, in this mouse
odel, CF mucus properties appear to be normalised when mucins
re secreted into buffers containing 115 mM HCO3− or 20 mM EDTA
Gustafsson et al., 2012), likely due to sequestration of Ca2+ ions that
llow mucins to expand. In addition, the volume of CF mucus (but
ot WT  mucus) increases in a HCO3−-enriched milieu, suggesting
hat CF mucus is incompletely expanded (Ambort et al., 2012).
The use of CF mice has provided a better understanding of, and
ew insights into the importance of HCO3− in the expansion of
ucins, particularly MUC2/Muc2. Whether this new knowledge
an be generalised to respiratory mucins is not yet clear because the
echanisms of polymerisation for MUC5AC and MUC5B have yet to
e determined. Intestinal mucus has been described as a chemical
el where the mucin matrix is formed from branched polymers (as
 result of N-terminal trimerisation; Fig. 2), resulting in a covalently
ross-linked gel network (Ambort et al., 2011; Hong et al., 2005).
n contrast, respiratory mucus is a physical gel in which linearmistry & Cell Biology 52 (2014) 136–145 141
polymers (as a result of N-terminal dimerization; Fig. 2) are
entangled and maintained in close proximity by electrostatic and
hydrophobic bonds (Sheehan et al., 2004; Thornton et al., 2008).
These different mucin network organisations may  be related to
the different functional requirements of their respective organs. In
the intestine, a tight mucin network with limited swelling capacity
might provide the best protection against the passage of large vol-
umes of gastric juice and partially digested food. On the other hand,
the respiratory tract might beneﬁt from airway mucus that is more
dynamic, allowing for the precise tuning of its rheological prop-
erties for optimal MCC  and, at the same time, ensuring bacterial
trapping.
3.2. Mucins in CF sputum
MUC5AC and MUC5B are the major gel-forming mucins pro-
duced in the lungs. Traditionally, their function has been viewed as
a ‘catch-all’ barrier to trap inhaled pathogens, particulates that are
continuously removed from the lungs by the coordinated beating
of cilia. The speciﬁc roles of MUC5AC and MUC5B have been largely
undetermined until recently. Further, the O-glycans coating these
mucins may  have diverged, evolutionary, to suit the needs of dif-
ferent species. Nonetheless, mouse models generated to examine
the role of mucins have revealed that Muc5ac provides protec-
tion against viral infection by acting as a decoy for viral receptors
(Ehre et al., 2012), while Muc5b is essential for MCC  and control-
ling bacterial infection (Muc5ac appears dispensable for these latter
functions) (Roy et al., 2013).
Analysis of CF sputum mucin content has revealed increased
MUC5AC and MUC5B concentrations (especially following exa-
cerbations) with MUC5B being the predominant mucin (Henke
et al., 2007; Horsley et al., 2013; Kirkham et al., 2002). Likewise,
immunohistochemical analysis has demonstrated increased con-
centrations of MUC5AC and MUC5B in the mucus plugs of CF
airways when compared to normal controls, again, with a higher
relative abundance of MUC5B (Burgel et al., 2007). Analysis of
the macromolecular properties of polymeric mucins in CF sputum
has shown that they are, on average, smaller compared to normal
mucins, likely due to the increased proteolytic activity of CF spu-
tum (Davies et al., 2002; Gupta and Jentoft, 1992; Rose et al., 1987;
Thornton et al., 1991). Intriguingly, a signiﬁcant genetic associa-
tion was  found between the length of the gene region encoding
the MUC5AC variable number of tandem repeats (VNTR) and CF
lung disease severity. However, the mechanisms underlying this
association remain obscure (Guo et al., 2011).
While CF mucus exhibits an altered composition of mucins,
there are no major changes in the macromolecular properties of
the mucins that might explain the sub-optimal mucus transport
properties. Mucins isolated from expectorated sputum have not
been reported to contain cross-linked species that could represent
the unexpanded, intragranular form. However, this molecular form
may  be more highly represented in adherent mucus plaques that
are not expectorated. Detailed molecular analysis of the lamellar-
structured plaques found in the CF pig airways might shed light on
this issue.
In contrast to normal respiratory mucus, the physical properties
of CF sputum are not wholly due to polymeric mucins but arise from
a complex interaction between the mucins and other sputum com-
ponents, including cell surface mucins, DNA and actin, as well as
inﬂammatory cells, bacteria, viruses and exoproducts (Matthews
et al., 1963; Voynow and Rubin, 2009). As a result, the airways
clearance of mucus that occurs through the coordinated beating
of cilia is compromised; however, the inﬂuence of these different
components on the aberrant rheological properties of sputum is
incompletely understood. The importance of mucins as opposed
to other macromolecules, particularly DNA, in determining the
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iscoelastic properties of CF sputum has been questioned (Henke
t al., 2004). However, the biophysical properties of mucins in CF
ecretions may  have been underestimated as a result of proteolytic
egradation, rendering rheological assays inaccurate and difﬁcult
o perform (Horsley et al., 2013). Moreover, proteolysis would
xplain observations suggesting mucin levels were lower in CF spu-
um than in healthy controls (Henke et al., 2004). Nonetheless, the
linical beneﬁts associated with treatments aimed at improving
ucus clearance have been clearly demonstrated in CF patients.
ypically, removal of thickened, adhered, mucus relies on physical
i.e., physiotherapy) and/or chemical (i.e., orally administered or
nhaled medications) therapies. Indeed, agents aimed at improving
ucin solubilisation will have an important role in the treatment
f CF lung disease.
. Therapies aimed at removing mucus from the lungs
Therapeutic strategies targeting the underlying cause of CF (i.e.,
FTR malfunction) offer important beneﬁts for CF patients as com-
ared to treating a wide range of symptoms. Thus, for the ﬁrst 10–15
ears following the discovery of the gene defect in CF, research
owards correcting the defect by gene therapy was  a major focus of
he CF community. However, it was eventually realised that gene
ransfer into diseased lungs was going to be more difﬁcult than
riginally anticipated, likely due to a physical barrier produced
y persistent mucus production and the short-lived expression
f the delivered therapeutic gene (Griesenbach et al., 2003). This
ed to greater exploration of alternative approaches for correcting
FTR malfunction. More recently, high-throughput screening pro-
rammes for the identiﬁcation of compounds capable of restoring
FTR function (see Section 2) were initiated by the Cystic Fibro-
is Foundation and lead to the discovery of Ivacaftor (Kalydeco
r VX-770) by Vertex Pharmaceuticals Inc. In vitro, Ivacaftor was
hown to increase Cl−-transport activity of cell lines expressing the
551D-CFTR mutation by increasing the time the channel remained
pen at the cell surface (i.e., it is a CFTR potentiator) (Van Goor
t al., 2009). Approximately 4–5% of CF patients carry the G551D
utation, limiting the impact of this oral drug on the global CF
opulation (McKone et al., 2003). Nevertheless, the treatment of
551D patients was associated with rapid and sustained improve-
ent in lung function (FEV1), reduced pulmonary exacerbations
nd respiratory symptoms, weight gain and increased sweat chlo-
ide concentration (Accurso et al., 2010; Ramsey et al., 2011). In
ddition, remarkable improvements in mucociliary clearance and
entilation defects have been shown during treatment with Iva-
aftor, suggesting that restitution of CFTR function is sufﬁcient to
ormalise the aberrant properties of mucus (Altes et al., 2012;
onaldson et al., 2013). Currently, two large clinical trials testing
he effects of Ivacaftor in combination with a CFTR corrector (VX-
09) in patients carrying the most common mutation (F508) are
eing conducted, based upon promising results in earlier studies,
ncluding a signiﬁcant improvement in lung function (Boyle et al.,
012).
Although correcting the underlying cause of CF is an overarch-
ng goal and appears to restore mucociliary clearance (Altes et al.,
012; Donaldson et al., 2013), alternative therapies that reduce air-
ay mucus obstruction (mucolytics) have been used for decades
nd novel therapies with this particular aim are currently being
nvestigated. The discovery that CF secretions contain substantial
mounts of extracellular DNA led to the development of a recom-
inant human DNase I (rhDNase or Dornase  or Pulmozyme®)
y Genentech Inc. in the 1990s. Initially, in vitro experiments con-
rmed that rhDNase decreased the viscosity of CF sputum (Shak
t al., 1990). Hence, rhDNase was tested in patients via inhalation
nd resulted in reduced exacerbations and respiratory symptoms,mistry & Cell Biology 52 (2014) 136–145
as well as improved FEV1 (Fuchs et al., 1994; Ramsey et al., 1993).
Over the past two  decades, rhDNase has been routinely used for CF
patient care as a means of clearing mucopurulent mucus, but alone
is not completely effective at alleviating the problems associated
with mucus overproduction and airway obstruction.
Since breaking down large DNA molecules improves respira-
tory symptoms, it is reasonable to postulate that reducing the size
of mucin polymers may  also beneﬁt airway clearance. The use of
N-acetylcysteine (NAC), a reducing agent that targets disulphide
bonds between mucin monomers and results in depolymerisation,
was approved in the 1960s and has been used as both an oral and
inhaled therapy. Surprisingly, inhalation of 20% NAC (1.2 M)  has not
yielded clinical beneﬁts, as reviewed by two  independent Cochrane
studies (Nash et al., 2009; Tam et al., 2013). It could be argued that
the lack of clinical beneﬁts with NAC is related to decreased mucin
concentration and that DNA is the major contributor to the prop-
erties of mucus in CF (Henke and Ratjen, 2007). Alternatively, NAC
might simply be a weak reducing agent that is ineffective at the con-
centrations deposited in the lower airways. Although this notion
needs to be further investigated, the development of more potent
reducing agents with increased efﬁcacy may  present important
clinical beneﬁts for CF patients.
Controlling the rate of mucin secretion has also been consid-
ered as a way to alleviate airway obstruction in CF. Understanding
the regulation of mucin granule exocytosis is essential for this
approach, and studies have shown similarities between the exo-
cytic mechanism in mucin-producing cells and other secretory
cells, such as neurons (Burgoyne and Morgan, 2003; Davis and
Dickey, 2008). Goblet cell secretagogues include P2Y2 receptor
agonists (ATP and UTP) and other agents that cause intracellular
Ca2+ mobilisation (Davis and Dickey, 2008; Kreda et al., 2007). The
identiﬁcation of downstream effectors of these secretagogues is
essential to advancing a mucin regulatory approach. Inhibition of
key components of the mucin exocytotic pathway, such as Munc13-
2, VAMP8, ROCK, MARCKS, can inhibit the release of mucin granules
and are currently being tested as potential drug targets (Jones et al.,
2012; Kreda et al., 2010, 2012; Singer et al., 2004; Zhu et al., 2008).
Perhaps the simplest approach to removing mucus from the
lungs is the use of osmotically active agents that rehydrate mucus.
Inhalation of hypertonic saline has been shown to reduce pul-
monary exacerbation, as well as improve FEV1 and MCC  (Donaldson
et al., 2006; Elkins et al., 2006). Another osmotically active agent,
mannitol, has recently been shown to yield similar beneﬁts (Bilton
et al., 2013; Daviskas et al., 2010). Given the diversity of CFTR muta-
tions, mucolytics, regulators of mucin secretion and osmotic agents
may  present several advantages over CFTR correctors/potentiators,
such as being cheaper and generic for all CFTR mutations. Additional
beneﬁts related to the removal of mucus, besides improved airﬂow,
might include reduced bacterial infection and inﬂammation.
5. Conclusions
Although much work is still needed to fully understand the
causal relationship between defective CFTR function and the pro-
duction of aberrant mucus, signiﬁcant progress towards this goal
has been made in recent years. Better insights of the CF pathogene-
sis cascade have arisen from a variety of sources, including primary
cell culture, animal models, and also human patients, with studies
performed on native tissues or intact organs. Hence, in some cases,
translation of these ﬁndings to the general CF population may not
be a straightforward process. In this review, we  have tentatively
summarised this progress, taking into account some inadvertent
omissions and misconceptions. The relationship between impaired
CFTR function and the production of sticky, viscous mucus in
several organs is not always obvious but can be related to two
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hysiological roles of the channel. By controlling water movement
nd HCO3− secretion, CFTR plays an essential role in the hydration
nd expansion of the mucins that are normally and continuously
roduced to protect mucosal surfaces. In CF, a water/electrolyte
mbalance compromises the formation of the mucus gel that lines
he mucosa and triggers a cascade of events with complex feedback
echanisms. In the lungs, the onset of mucus obstruction, infection
nd inﬂammation can be life-threatening. Hence, removal of mucus
nd mucopurulent material from the lungs is crucial for CF patients.
urrently, translational research is being conducted to identify a
umber of compounds that offer promising pharmacotherapy for
F. More speciﬁcally, inhaled mucolytic agents have the potential
o improve airﬂow, prevent bacterial growth and reduce inﬂamma-
ion and tissue damage. Targeting mucin intramolecular disulphide
onds using reducing agents is an interesting approach that could
lso beneﬁt patients suffering from chronic obstructive pulmonary
isease (COPD). Conceptually, this type of treatment would be used
s an acute therapy (e.g., for exacerbation) rather than on a daily
asis. Importantly, safety issues related to the reduction of other
isulphide bonds would have to be considered. For example, the
peciﬁcity of the target (i.e., mucins) over other luminal proteins
ill be difﬁcult to achieve and necessitate monitoring. However,
he side effects of such a treatment might be outweighed by its
linical beneﬁts if it can effectively “clean” the lungs.
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